Simple, one-page factsheet developed in 2012 that defines treatment as prevention and what it can achieve.
What is Treatment as Prevention and What is it Not?
Data Safety Monitoring Boards (DSMBs)
Clinical trials are monitored and regulated by a variety of entities, including independent bodies that review the trial protocol and data on an ongoing basis to ensure that the trial is ethical and should continue. This fact sheet is for advocates who would like to learn more about how these entities work, what they do, and what impact their recommendations can have on clinical trials.
Treatment as Prevention: Frequently asked questions
This FAQ was developed with input from the National Empowerment Network of People Living with HIV (NEPHAK) and Health GAP on the basis of national PLHIV dialogues on treatment as prevention conducted throughout Kenya. The questions and answers contain information relevant for a global audience—but have been written specifically for individuals living and working in low and middle income countries
Pharmacokinetics and Pharmacodynamics: A primer for HIV prevention advocates
Pharmacokinetics (PK) is the study of what happens to a drug when it is taken into the body; pharmacodynamics (PD) is the study of what happens to the body when a drug is taken. PK/PD research is a central aspect of the search for ARV-based prevention, and this factsheet is for advocates looking to understand some of the basic terms, aims and objectives of PK and PD studies.
FDA’s Advisory Committee Review of Daily Oral Truvada as PrEP to Reduce the Risk of HIV Infection: An advocate’s primer for public participation
This primer was developed to help advocates understand the mechanism of the US Food and Drug Administration’s external advisory committee. It was specifically developed in preparation for the US FDA review of Truvada for use as PrEP in 2012. It offers a guide to the workings of the external advisory committee (a set of outside experts who make recommendations) and ways for civil society to participate in the process.
Frequently Asked Questions on Non-Surgical Devices for Voluntary Medical Male Circumcision for HIV Prevention
Basic information on non-surgical devices with a focus on the implications of WHO prequalification and next steps for product introduction.
Understanding the Results of CAPRISA 004
A 2010 document discussing the results of the CAPRISA 004 microbicide gel trial. It explores the implications of the data and outlines the next steps in evaluating tenofovir gel.
PrEP: A new option for women for safer loving
A brochure designed for women who want information on whether PrEP is the right prevention option for them.
Influencing PEPFAR COPs: An Advocate’s Guide
A two-page resource designed for advocates working in the US and in countries receiving PEPFAR funding. It contains background information and an infographic on how PEPFAR Country Operating Plans are developed and how advocates can influence them.
Adherence in HIV Prevention Research: A primer for HIV prevention advocates
A two-page resource providing simple explanations of how adherence is defined and measured in biomedical HIV prevention trials, with a focus on PrEP and microbicides.